Clinical trials are also underway to target mutant IDH1 and IDH2 in AML, gliomas, myelodysplastic syndrome, and other solid tumors (Mondesir et al., 2016; Vander Heiden and DeBerardinis, 2017). Here, IDH2 is linked to glioma.